Search Results for “EU” – Page 8 – media

Under the great changes! Thinking about the development strategy of pharmaceutical companies

1. Cycles exist objectively, but they are not impossible to cross In recent years, the concept we first used was the “new normal”. The term “new normal” actually lowers social expectations in advance. Later, many experts introduced the concept of “cycle” with the intention of incorporating the current economic situation into a historical cycle. Admittedly, economic development has cycles, and even the spread of viruses has cycles. However, “today’s economic and social conditions should mainly be the result of active choices made by decision-makers. Cyclical factors have an effect but are not decisive, or the adjustment of development direction “encounters” cyclical factors”-excerpted from Du Chen’s “Our Times and Us in the Times”. 2. The current difficulties may only be the initial stage The “new cycle” has just begun, and we must be prepared for long-term hard work. Combining data from the National Bureau of Statistics, Minnet, IQVIA, etc., the average ...
- Source: drugdu
- 52
- September 4, 2024
Yuheng Pharmaceuticals sees a turnaround

Yuheng Pharmaceutical, founded by Zhu Jiman, the “Northeast Medicine King”, once became famous in the industry through continuous large-scale mergers and acquisitions of many pharmaceutical companies such as Auno Pharmaceutical and Shanghai Huatuo. In the end, it fell into a downturn due to frequent mergers and acquisitions. Recently, Yuheng Pharmaceutical handed in its first semi-annual report after the reorganization. The net profit attributable to the parent company in the first half of 2024 was 125 million yuan, a year-on-year increase of 342.39%, and a substantial increase in profits. How did Yuheng Pharmaceutical recover so quickly? We have to talk about PD-1. There are many competitors in the PD-1/L1 field. In June 2024, the listing application of Enlangsubai monoclonal antibody of Shijiazhuang Pharmaceutical Group was officially approved. So far, there are at least 15 PD-1/L1 monoclonal antibodies approved for listing in China. The PD-1/L1 track, which is being chased by major ...
- Source: drugdu
- 64
- September 4, 2024
Warner Pharmaceutical’s Half Year Report Achieves New High in Total Assets, Highly Recommended by Securities Firms

Source: Securities Times · E Company Latest price: 38.25 Price fluctuation: -0.75 Price range: -1.92% Transaction volume: 4481 lots Transaction amount: 17.06 million Turnover rate: 0.48% Price to earnings ratio: 15.9 Total market value: 3.59 billion On August 31st, Warner Bros. Pharmaceutical (688799. SH) released its 2024 semi annual report, achieving a revenue of 739 million yuan in the first half of the year, a year-on-year increase of 2.34%; Realize a net profit attributable to the parent company of 113 million yuan, a year-on-year increase of 0.52%. The basic earnings per share are 1.20 yuan. Simultaneously disclosed is the 2023 annual profit distribution plan, in which the company plans to distribute a cash dividend of 9 yuan (including tax) for every 10 shares to all shareholders, totaling 84.42 million yuan (including tax). If this profit distribution plan is approved by the shareholders’ meeting, the company will distribute a total of ...
- Source: drugdu
- 76
- September 3, 2024
HEC Pharmaceuticals and Shamshi Technology held a joint laboratory unveiling ceremony

On August 28, 2024, HEC Pharmaceuticals and Deepin Technology held a joint laboratory unveiling ceremony. The joint laboratory of HEC Pharmaceuticals and Deepin Technology focuses on high-value R&D scenarios and technical R&D bottlenecks in the field of biopharmaceuticals, promoting science and technology from The complete closed loop from source innovation to industrial implementation forms a complete closed loop, jointly exploring the industrial transformation and verification of cutting-edge AI technologies. The unveiling ceremony announced the cooperation relationship between the two parties and promoted close cooperation between the two parties in future multi-level projects. Co., Ltd. (hereinafter referred to as East Sunshine Pharmaceutical), as the domestic anti-influenza “top” brand, its anti-influenza drug Kewei® is the top brand of oseltamivir phosphate, and in February this year, it was awarded the The company has obtained three certifications: “the largest oseltamivir production base in the world”, “the largest oseltamivir production in the world in the ...
- Source: drugdu
- 74
- September 1, 2024
myTomorrows and Pancreatic Cancer Europe partner on clinical trials

The partnership will improve care for patients with pancreatic cancer myTomorrows, a global health technology company connecting patients with all possible treatment options, has announced a new partnership with Pancreatic Cancer Europe, a multi-stakeholder platform that brings together experts from all over Europe to improve care for patients with pancreatic cancer. Through the new partnership, Pancreatic Cancer Europe (PCE) will utilise myTomorrows’ database of ongoing clinical trials to equip patients, caregivers and healthcare professionals (HCPs) with up-to-date, accessible information about pre-approval treatments that may be relevant to them. The partnership with the European patient advocacy group and myTomorrows will help to expand access to all possible treatment options for patients suffering from a variety of life-threatening illnesses. For pancreatic cancer patients and HCPs, the partnership will help make the process of identifying and understanding the existing clinical trial options easier. Pancreatic cancer is the fourth leading cause of cancer deaths, ...
- Source: drugdu
- 86
- August 30, 2024
MSD snags European approval for pulmonary arterial hypertension therapy

The European Commission (EC) has granted approval to Merck & Co’s (MSD) Winrevair (sotatercept) to be used as a combination therapy for the treatment of adults with functional class II or III pulmonary arterial hypertension (PAH). The approval was awarded based on data from STELLAR, a Phase III study (NCT04576988) that evaluated 323 adult participants with functional class II or III PAH, as determined by the World Health Organization (WHO), as per the 26 August press announcement, The European approval for the subcutaneously administered therapy follows one from the US Food and Drug Administration (FDA) in March 2024 for the same group of PAH patients. According to GlobalData’s consensus forecasts, Winrevair is expected to generate total sales of $6.3bn in 2030. GlobalData is the parent company of Pharmaceutical Technology. Notably, a day before the approval of Winrevair, the FDA granted approval to Johnson & Johnson’s (J&J) Opsynvi (macitentan + tadalafil). ...
- Source: drugdu
- 95
- August 28, 2024
FDA Grants Fast Track Designation to Clarity Pharmaceuticals’ Novel Treatment for PSMA-Positive Prostate Cancer Lesions

By Don Tracy, Associate Editor 64Cu-SAR-bisPSMA has demonstrated advantages over current diagnostic tools, such as higher tumor uptake, next-day imaging, and a longer half-life in PET imaging of PSMA-positive prostate cancer lesions, Clarity says. The FDA has granted Fast Track designation to Clarity Pharmaceuticals’ 64Cu-SAR-bisPSMA, a novel imaging agent designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions with suspected metastasis. According to the company, the agent, which was supported by promising clinical results, has demonstrated advantages over current diagnostic tools, such as higher tumor uptake, next-day imaging, and a longer half-life, allowing for centralized production and flexible patient scheduling.1 “Receiving Fast Track Designation for 64Cu-SAR-bisPSMA is a significant milestone, especially as we are actively recruiting into our first registrational Phase III trial, CLARIFY, and preparing for an End of Phase meeting with the FDA for a second pivotal Phase III trial with ...
- Source: drugdu
- 75
- August 27, 2024
Q&A with Oren Gilad, CEO of Aprea Therapeutics

By Mike Hollan Gilad discusses the ways that this method can be used to treat various cancers without putting patients through the side effects of chemotherapy. Precision medicine is gaining momentum in the life sciences industry. It’s also changing the way that researchers are approaching new treatments and therapies. Pharmaceutical Executive spoke with Oren Gilad, PhD, president and CEO of Aprea Therapeutics, about some of the ways that the company is approaching cancer treatment with this new mindset. Pharmaceutical Executive: Can you discuss the concept of synthetic lethality and how it relates to your work? Oren Gilad: Synthetic lethality is a concept where the combination of two genetic mutations leads to cell death, whereas each mutation on its own would not be lethal. Cancer cells often have specific genetic mutations that normal cells do not carry, generally because they exist because a normal mutated to become cancer. So, there’s already ...
- Source: drugdu
- 60
- August 26, 2024
CPhI Worldwide Milan -Discover the future of pharma in Europe

Organizer: Informa Markets Date: October 8-10, 2024 Venue: Strada Statale Sempione, 28, 20017 Rho MI Exhibition Hall: Fiera Milano Rho Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, Hormones, Sulfonamides, Antipyretics and Analgesics, Tetracyclines, Amino Acids and Their Derivatives, Chloramphenicols, Digestive System Drugs, Other Anti-Infective Agents Excipients and Dosage Forms: Excipients, Glidants, Enteric Materials Natural Extracts: Plant Extracts, Animal Extracts, Traditional Chinese Medicine Ingredients, Functional Food Ingredients, Health Product Ingredients Bioproducts and Reagents: Antibodies, Nucleic Acid/Protein Synthesis, Cell Biology Detection, Animal/Plant Proteins/Antigens/Peptides, Nucleic Acid Analysis, Libraries and Constructions, Biochemistry Technical Services: Project Design/Thesis Outsourcing, Cell Biology, Biochips, Instrument Testing/Maintenance, Molecular Biology, Microbiology Exhibition CPhI Worldwide Mila: CPhI Worldwide is the market leader in the global pharmaceutical ingredients industry. First held in 1990, it has been held annually in major developed cities in Europe. It is a trade exhibition with a large scale, high standard, and well-known reputation in the ...
- Source: drugdu
- 416
- August 23, 2024
FDA Approves Incyte and Syndax Pharmaceuticals’ Niktimvo for Treating Chronic Graft-Versus-Host Disease

By Don Tracy, Associate Editor Approval of Niktimvo was based on positive data from the AGAVE-201 study, which demonstrated a 75% response rate in patients with chronic graft-versus-host disease.The FDA has approved Incyte Sundax Pharmaceuticals’ Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for treating chronic graft-versus-host disease (GVHD) in patients who have not responded to at least two previous lines of systemic therapy. According to both companies, Niktimvo is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD. The approval was based on promising results from the AGAVE-201 study.1 “With the approval of Niktimvo, patients with chronic GVHD whose disease has progressed after prior therapies, now have a new treatment option with a novel mechanism of action to help address the serious and devastating complications associated with this disease,” said Hervé Hoppenot, CEO, Incyte, in a press release. “Niktimvo is Incyte’s second approved treatment for ...
- Source: drugdu
- 86
- August 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.